CAPAC® Platform Programs
Oncology (specifics not fully disclosed)
Phase 1Active
Key Facts
About Shasqi
Shasqi is developing a next-generation drug delivery platform based on click chemistry, a Nobel Prize-winning technology, to precisely target cancer therapies. Its CAPAC® platform employs a two-step, pre-targeting approach: first, a 'clickable binder' localizes to the tumor, then a systemically administered 'clickable payload' (chemotherapy or radioisotope) is activated only upon clicking with the binder at the tumor. This modular system is designed to improve the therapeutic index of cancer drugs beyond current standards like Antibody-Drug Conjugates (ADCs). The company has validated its platform in the clinic and is advancing a pipeline of novel therapies for cancers with limited treatment options.
View full company profile